The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease

Diabetes Care

Volumn 28, Issue 7, 2005, Pages 1668-1674

  Beishuizen, Edith D ^a   Tamsma, Jouke T ^a   Jukema, J Wouter ^a   Van De Ree, Marcel A ^b   Van Der Vijver, J Carel M ^c   Meinders, A Edo ^a   Huisman, Menno V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; CERIVASTATIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTERY DIAMETER; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; B SCAN; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FLOW MEDIATED DILATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; BLOOD FLOW VELOCITY; BODY MASS; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; ECHOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

BLOOD FLOW VELOCITY; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLACEBOS; PYRIDINES; SIMVASTATIN;

EID: 24944587279     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.7.1668     Document Type: Article

References (42)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
2. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R: Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40:505-510, 2002
3. Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108:1527-1532, 2003
4. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179, 1994
5. Baron AD: Vascular reactivity. Am J Cardiol 84:25J-27J, 1999
6. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91:1314-1319, 1995
7. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26:1235-1241, 1995
8. Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, Pfohl M, Herdeg C, Oberhoff M, Haering HU, Karsch KR: Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J 138:731-739, 1999
9. Teragawa H, Kato M, Kurokawa J, Yamagata T, Matsuura H, Chayama K: Usefulness of flow-mediated dilation of the brachial artery and/or the intima-media thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. Am J Cardiol 88:1147-1151, 2001
10. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F: Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 86:207-210, 2000
11. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A: The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 42:1037-1043, 2003
12. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA: Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41:1769-1775, 2003
13. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105:1567-1572, 2002
14. Fathi R, Haluska B, Isbel N, Short L, Marwick TH: The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 43:616-623, 2004
15. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS: Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25:1055-1059, 2002
16. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211-1218, 2002
17. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
18. Goodfellow J, Ramsey MW, Luddington LA, Jones CJ, Coates PA, Dunstan F, Lewis MJ, Owens DR, Henderson AH: Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ 312:744-745, 1996
19. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780-1784, 2000
20. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS: Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 84:3212-3216, 1999
21. Sheu WH, Juang BL, Chen YT, Lee WJ: Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 22:1224-1225, 1999
22. Henry RM, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Kamp O, Bouter LM, Stehouwer CD: Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not: the Hoorn Study. Atherosclerosis 174:49-56, 2004
23. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33:234-241, 1999
24. Laufs U, La F, V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135, 1998
25. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial Superoxide anion formation. Arterioscler Thromb Vasc Biol 20:61-69, 2000
26. Vogel RA, Corretti MC, Plotnick GD: Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 77:37-40, 1996
27. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV: Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 27:2887-2892, 2004
28. van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD: Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, doubleblind, placebo-controlled trial. Diabetes Care 25:1211-1216, 2002
29. West SG, Wagner P, Schoemer SL, Hecker KD, Hurston KL, Likos KA, Boseska L, Ulbrecht J, Hinderliter AL: Biological correlates of day-to-day variation in flow-mediated dilation in individuals with type 2 diabetes: a study of test-retest reliability. Diabetologia 47:1625-1631, 2004
30. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327:307-310, 1986
31. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A: The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 89:740-747, 2004
32. Sheu WH, Chen YT, Lee WJ: Improvement in endothelial dysfunction with LDL cholesterol level <80 mg/dl in type 2 diabetic patients. Diabetes Care 24:1499-1501, 2001
33. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A: Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379, 2001
34. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, DeanneldJ, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257-265, 2002
35. Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV: Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol 94:294-299, 2004
36. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y: Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. Int J Cardiol 94:111-117, 2004
37. Vijan S, Hayward RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140:650-658, 2004
38. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neu HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
39. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ: Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 52:299-305, 2001
40. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ: Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Artenoscler Thromb Vasc Biol 22:799-804, 2002
41. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A: The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52:173-180, 2003
42. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Artenoscler Thromb Vasc Biol 23:729-736, 2003